Answers are grounded in this paper and cite their sources.
Background: Induction chemotherapy (IC) substantially reduces tumor burden in locoregionally advanced nasopharyngeal carcinoma (LA-NPC), enabling radiotherapy target volume optimization based on post-IC tumor volume. However, most existing studies have focused on the primary tumor, with limited attention to cervical nodal targets. This study aimed to evaluate the long-term efficacy and safety of response-adapted nodal dose de-escalation in patients achieving complete nodal response after IC without high-risk features. Methods: A retrospective analysis was conducted on 214 patients with stage II-IVA NPC treated with IC followed by intensity-modulated radiotherapy (IMRT) between June 2018 and December 2020. Patients with complete nodal response post-IC and no high-risk features-defined as necrosis, extranodal extension, nodal size ≥3 cm, or multiple nodes within a single drainage level-were selected for dose de-escalation (50-64 Gy) to the nodal gross tumor volume (GTVnd) and the corresponding clinical target volume (CTV). Treatment outcomes, Epstein-Barr virus (EBV) DNA kinetics, dosimetric parameters, and toxicities were systematically analyzed. Results: 56.3%) and improved survival outcomes. Conclusions: For LA-NPC patients achieving nodal complete response after IC and without high-risk features, tailored dose reduction to nodal GTV and CTV achieved excellent locoregional control with reduced long-term toxicity.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: